Johnson & Johnson Secures EC Approval for Amivantamab-Lazertinib Combo as First-Line Treatment for EGFR-Mutated NSCLC

30 December 2024 | Monday | News

Phase 3 MARIPOSA Study Confirms 30% Reduction in Disease Progression Risk and Enhanced Response Duration
Picture Courtesy | Public Domain

Picture Courtesy | Public Domain

 

Janssen-Cilag International NV, a Johnson & Johnson company,  announced the European Commission (EC) approval of RYBREVANT®▼ (amivantamab) combined with LAZCLUZE®▼ (lazertinib) as a first-line treatment for advanced non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution mutations.

This chemotherapy-free regimen, evaluated in the Phase 3 MARIPOSA study, demonstrated a 30% reduction in the risk of disease progression or death versus osimertinib monotherapy. The study also revealed a nine-month improvement in median duration of response (25.8 months vs. 16.8 months) for the combination therapy.

The approval underscores Johnson & Johnson commitment to addressing unmet medical needs in lung cancer, Europe's leading cause of cancer-related deaths, by offering innovative therapies tailored to genetic drivers of the disease. The decision marks significant progress for patients, potentially setting a new standard of care in EGFR-mutated NSCLC.

The safety profile was consistent with prior studies, with most adverse events being manageable. A pending EC decision on a standalone Marketing Authorisation for lazertinib follows a positive CHMP opinion.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close